Novel pamoate salts of certain 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-diones and pharmacologically acceptable solvates thereof are devoid of the weight loss and hepatocyte changes in the rat which limited to marginally effective levels the permitted clinical doses of the corresponding hydrochlorides in the treatment or prophylaxis of stress-related affective disorders such as anxiety, depression, migraine and sleep apnoea. The preferred pamoate salts are 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate and, especially, 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.
某些 3-苯基-3-二甲基
氨基烷基-
4,4-二甲基哌啶-2,6-二酮的新型帕莫阿特盐及其药理上可接受的溶解物不会导致大鼠体重减轻和肝细胞变化,而这些变化将相应盐酸盐的允许临床剂量限制在治疗或预防与压力有关的情感障碍(如焦虑、抑郁、偏头痛和睡眠呼吸暂停)的勉强有效
水平。首选的
帕莫酸盐是 3(3,5-二
甲氧基苯基)-3-(3-二甲基
氨基丙基)-
4,4-二甲基哌啶-2,6-二酮
帕莫酸酯,特别是 3(3-
甲氧基苯基)-3-(3-二甲基
氨基丙基)-
4,4-二甲基哌啶-2,6-二酮
帕莫酸酯。